Related Experiment Videos
[Pneumocystis carinii pneumonia in AIDS. New concepts for an old problem]
1Hospital F. Santojanni, Buenos Aires, Argentina. helios@overnet.com.ar
Abstract:
Pneumocystis carinii (PC) is an ubiquitous pathogen phylogenetically considered a fungus. In individuals with T-cell deficiency, PC produces typically an interstitial pneumonia. The primary infection is, perhaps, transmitted airborne, and is acquired during early infancy. PC was a rare cause of disease until the advent of AIDS. In susceptible patients infected with HIV it remains a major cause of morbidity and mortality despite appropriate prophylaxis and treatment. Mutations in the gene that encodes the enzyme dihydropteroate synthase are seemingly accountable for the failure of prophylaxis in some individuals. The incidence of new cases of PC pneumonia (PCP) in patients with infection with HIV has dropped substantially since the advent of highly active antiretroviral therapy (HAART). Ongoing trials are designed to study the effect of withdrawing prophylaxis for PCP in patients whose T-cell count has risen over 200/mm3 in response to HAART.
Insights
Pneumocystis pneumonia (PCP) is a significant risk for individuals with T-cell deficiencies, particularly those with HIV/AIDS. Advances like HAART have reduced PCP incidence, and trials are exploring stopping prophylaxis in immune-recovering patients.
Area of Science:
- Medical Mycology and Infectious Diseases
- Immunology and Virology
Context:
- Pneumocystis carinii (PC), a fungus, causes interstitial pneumonia in T-cell deficient individuals.
- PC pneumonia (PCP) was rare until the emergence of HIV/AIDS, becoming a major cause of morbidity and mortality in these patients.
- Despite prophylaxis and treatment, PCP remains a threat, with some cases linked to dihydropteroate synthase gene mutations affecting drug efficacy.
Purpose:
- To review the epidemiology and clinical significance of Pneumocystis pneumonia (PCP) in immunocompromised patients.
- To discuss the impact of HIV/AIDS on PCP incidence and outcomes.
- To highlight the role of highly active antiretroviral therapy (HAART) in reducing PCP and ongoing research into prophylaxis withdrawal.
Summary:
- Pneumocystis carinii is an opportunistic fungal pathogen causing severe pneumonia in individuals with compromised T-cell immunity.
- The incidence of PCP in HIV-infected patients has significantly decreased with the widespread use of HAART.
- Current research is investigating the safety and efficacy of discontinuing PCP prophylaxis in HIV patients who have regained immune function (T-cell count > 200/mm3) due to HAART.
Impact:
- Understanding PCP pathogenesis and risk factors is crucial for managing immunocompromised populations.
- HAART has transformed the prognosis for HIV patients, substantially reducing PCP-related complications.
- Findings from ongoing trials on prophylaxis withdrawal could alter clinical guidelines and reduce treatment burden for eligible patients.